We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Insulet (PODD - Free Report) will report quarterly earnings of $0.57 per share in its upcoming release, pointing to a year-over-year increase of 50%. It is anticipated that revenues will amount to $463.13 million, exhibiting an increase of 16.8% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Insulet metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Revenue- Total Omnipod' will reach $455.38 million. The estimate indicates a year-over-year change of +19.7%.
The consensus estimate for 'Revenue- Drug Delivery' stands at $4.36 million. The estimate points to a change of -72.7% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenue- International Omnipod' of $116.35 million. The estimate indicates a change of +12.2% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- U.S. Omnipod' will likely reach $339.05 million. The estimate suggests a change of +22.5% year over year.
Insulet shares have witnessed a change of -0.2% in the past month, in contrast to the Zacks S&P 500 composite's -2.9% move. With a Zacks Rank #1 (Strong Buy), PODD is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Insulet (PODD - Free Report) will report quarterly earnings of $0.57 per share in its upcoming release, pointing to a year-over-year increase of 50%. It is anticipated that revenues will amount to $463.13 million, exhibiting an increase of 16.8% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Insulet metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Revenue- Total Omnipod' will reach $455.38 million. The estimate indicates a year-over-year change of +19.7%.
The consensus estimate for 'Revenue- Drug Delivery' stands at $4.36 million. The estimate points to a change of -72.7% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenue- International Omnipod' of $116.35 million. The estimate indicates a change of +12.2% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- U.S. Omnipod' will likely reach $339.05 million. The estimate suggests a change of +22.5% year over year.
View all Key Company Metrics for Insulet here>>>
Insulet shares have witnessed a change of -0.2% in the past month, in contrast to the Zacks S&P 500 composite's -2.9% move. With a Zacks Rank #1 (Strong Buy), PODD is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>